Genotype-guided antiplatelet therapy for stroke patients
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether using a rapid genetic test to choose antiplatelet medication can improve outcomes for people who have had a stroke or mini-stroke. The test checks a gene that affects how your body processes a common antiplatelet drug, so your doctors can pick the safest and most effective medicine for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You had a stroke or mini-stroke and can start dual antiplatelet therapy safely
- You arrived at the hospital within 24 hours of your symptoms starting, or within 24 to 96 hours if you are already on or will start dual antiplatelet therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This study looks at whether certain blood tests can predict if the antiplatelet drug clopidogrel (Plavix) will work well in people who have had a mild stroke or a mini-stroke (TIA). The goal is to help doctors choose the best treatment for each person.
This study tests whether adjusting blood-thinner medication based on a blood test can better prevent another stroke in people who recently had a minor stroke or a high-risk mini-stroke. It aims to find the safest and most effective dose for each patient.
This study looks at whether a blood test can show how well clopidogrel works for you after a stent is placed in a narrowed brain artery. It aims to find out if people who don't respond well to clopidogrel have a higher chance of another stroke.
This trial tests whether a quick genetic test can help choose the right antiplatelet medicine for people who have had a mild stroke or a high-risk mini-stroke (TIA). The goal is to see if this personalized approach is possible in a hospital setting.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.